OPKO announces submission of Rayaldee(TM) New Drug Application to FDA
OPKO Health announced it has submitted a NDA for oral Rayaldee to the FDA. The NDA requests marketing approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. May 29, 2015